Zolgensma will compete against another highly expensive drug - Biogen's Spinraza (nusinersen), while Roche is also developing a potential rival called risdiplam that is slated for a European ...

Spinraza (nusinersen) – is one result of that effort. The antisense oligonucleotide works by modulating alternative splicing of the SMN2 exon which is mutated in the disease. This is however ...